Chandra Bhagat Pharma Ltd Stock Price Today (NSE: CBPL)
Fundamental Score
Chandra Bhagat Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Chandra Bhagat Pharma Ltd share price today is ₹43.38, up +4.99% on NSE/BSE as of 7 August 2026. Chandra Bhagat Pharma Ltd (CBPL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹25.88 (Cr). The 52-week high for CBPL share price is ₹59.00 and the 52-week low is ₹29.70. At a P/E ratio of 8.48x, CBPL is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 9.67% and a debt-to-equity ratio of 0.50.
Chandra Bhagat Pharma Ltd Share Price Chart — NSE/BSE Historical Performance
Chandra Bhagat Pharma Ltd share price chart: -13.84% return over the past month. 52-week high ₹59.00, 52-week low ₹29.70.
Chandra Bhagat Pharma Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹43.38 | ₹43.38 | ₹43.38 | ₹43.38 | 4.00K (Cr) | |
| ₹41.00 | ₹41.32 | ₹41.00 | ₹41.32 | 8.00K (Cr) | |
| ₹39.36 | ₹39.36 | ₹39.36 | ₹39.36 | 0.00 (Cr) | |
| ₹37.50 | ₹39.36 | ₹37.50 | ₹39.36 | 2.00K (Cr) | |
| ₹37.50 | ₹37.50 | ₹37.50 | ₹37.50 | 1.00K (Cr) | |
| ₹37.92 | ₹37.92 | ₹37.92 | ₹37.92 | 3.00K (Cr) | |
| ₹33.00 | ₹36.12 | ₹33.00 | ₹36.12 | 7.00K (Cr) | |
| ₹32.08 | ₹34.60 | ₹32.08 | ₹34.40 | 14.00K (Cr) | |
| ₹35.28 | ₹35.28 | ₹32.15 | ₹33.22 | 13.00K (Cr) | |
| ₹33.60 | ₹33.60 | ₹33.60 | ₹33.60 | 8.00K (Cr) |
Chandra Bhagat Pharma Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹37.50 | ₹43.38 | ₹37.50 | ₹43.38 | +15.68% | |
| ₹44.01 | ₹44.80 | ₹31.65 | ₹37.92 | -13.84% | |
| ₹46.20 | ₹46.20 | ₹41.80 | ₹46.00 | -0.43% | |
| ₹31.09 | ₹46.20 | ₹29.70 | ₹44.00 | +41.52% | |
| ₹32.00 | ₹37.00 | ₹30.12 | ₹33.00 | +3.13% | |
| ₹39.50 | ₹39.50 | ₹29.95 | ₹30.50 | -22.78% | |
| ₹42.20 | ₹42.20 | ₹36.20 | ₹39.45 | -6.52% | |
| ₹39.90 | ₹42.10 | ₹39.19 | ₹42.10 | +5.51% | |
| ₹35.00 | ₹48.95 | ₹33.00 | ₹41.25 | +17.86% | |
| ₹38.00 | ₹40.01 | ₹38.00 | ₹38.70 | +1.84% | |
| ₹37.10 | ₹48.00 | ₹37.10 | ₹41.12 | +10.84% | |
| ₹55.00 | ₹55.00 | ₹43.00 | ₹43.00 | -21.82% |
AI Research Briefing
Powered by Gemini · 2026-04-10
CBPL is a micro-cap value trap with weak fundamentals and overvaluation.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. The most recent news relates to routine disclosures.
CORE STORY (THE REAL GAME)
CBPL is not a growth story, but a micro-cap play on promoter holding increase and potential takeover speculation. It's a gamble on someone seeing value where the market currently doesn't.
- Promoter holding increase
- Micro-cap size
- Sector tailwinds
- Takeover offer
- Significant order win
- Turnaround in financials
- Micro/SME cap - liquidity risk
- High P/E ratio
- Weak financials
Promoter increased holding by 0.99%. FII and DII holdings are negligible.
Indian pharmaceutical industry is projected to grow, but CBPL is underperforming.
No - Free Cash Flow 5Y: ₹22.63 Cr, but latest quarter is weak.
Unless there's a significant turnaround in financials or a takeover offer, CBPL's outlook remains bleak. Expect continued underperformance.
Primary Thesis Risk
Reliance on hope rather than fundamentals.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Chandra Bhagat Pharma Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Chandra Bhagat Pharma Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CBPL across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Attractive Valuation (P/E: 8.48 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (1429.41%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (316.19%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Excellent EPS Growth (74.22% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (74.22% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Balanced Promoter Holding (73.02%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Below-Average Return on Equity (9.67%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Margin Pressure Concerns (0.25%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Chandra Bhagat Pharma Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Chandra Bhagat Pharma Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Chandra Bhagat Pharma LtdChandra Bhagat ...Selected✓ CBPL • 542934 | 68.3/100 | ₹43.38₹43 | ₹25.88₹25.88 | 8.48Average 8.5 Average | 9.67%Poor 9.67% Poor | 12.14%Average 12.14% Average | 0.50Excellent 0.5 Excellent | 74.22%Excellent 74.22% Excellent | 10.46%Good 10.46% Good | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Chandra Bhagat Pharma Ltd PE Ratio History
Historical price-to-earnings ratio for CBPL — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹2.03 | ₹65.67 | 32.3x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Chandra Bhagat Pharma Ltd Quarterly Performance
Latest quarterly metrics for CBPL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
316.19%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
1429.41%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
10.46%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
74.22%
Compounded annual net profit growth over 5 years
Chandra Bhagat Pharma Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for CBPL — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Chandra Bhagat Pharma Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Chandra Bhagat Pharma Ltd (CBPL) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Chandra Bhagat Pharma Ltd
About CBPL (Chandra Bhagat Pharma Ltd)
Chandra Bhagat Pharma Ltd is a dynamic and rapidly expanding pharmaceutical company dedicated to providing high-quality healthcare solutions across a diverse range of therapeutic a...reas. With a steadfast commitment to innovation and patient well-being, CBPL focuses on the development, manufacturing, and commercialization of essential medicines that address unmet medical needs. Our portfolio encompasses a broad spectrum of formulations, from life-saving injectables to convenient oral dosages, ensuring accessibility and ease of administration for healthcare professionals and patients alike. We strive to deliver impactful therapies that improve outcomes and enhance the quality of life for individuals around the world, building a reputation for reliability, integrity, and excellence in the pharmaceutical industry. CBPL is deeply invested in forging strong partnerships with healthcare providers and institutions to ensure seamless delivery of our products and to stay abreast of evolving medical needs. We maintain a robust distribution network that enables us to efficiently reach hospitals, clinics, and pharmacies throughout India and select international markets. Our highly skilled and dedicated team of professionals is driven by a shared vision of making a positive difference in the lives of patients. We are committed to upholding the highest standards of quality and safety in all aspects of our operations, from sourcing raw materials to manufacturing processes and quality control measures. Our unwavering dedication to research and development is at the heart of our growth strategy. CBPL continuously explores opportunities to expand our product pipeline with novel therapies and innovative drug delivery systems. We believe in investing in cutting-edge technologies and fostering a culture of scientific excellence to drive advancements in healthcare. Through strategic collaborations and partnerships, we seek to leverage the expertise of leading researchers and institutions to accelerate the development of groundbreaking solutions that address the most pressing medical challenges of our time, ultimately contributing to a healthier future for all.
Company Details
Key Leadership
CBPL Share Price: Frequently Asked Questions
What is the current share price of Chandra Bhagat Pharma Ltd?
Chandra Bhagat Pharma Ltd (CBPL) trades at ₹43.38 on NSE and BSE. Market cap ₹25.88 (Cr). Educational data only.
What is the P/E ratio of Chandra Bhagat Pharma Ltd?
Chandra Bhagat Pharma Ltd has a P/E of 8.48x vs industry average 34.89x.
What is the Bull Run score for Chandra Bhagat Pharma Ltd?
Chandra Bhagat Pharma Ltd has a Bull Run score of 68.3/100 based on 25+ financial parameters.
Does Chandra Bhagat Pharma Ltd pay dividends?
Chandra Bhagat Pharma Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Chandra Bhagat Pharma Ltd?
Chandra Bhagat Pharma Ltd has ROE of 9.67%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Chandra Bhagat Pharma Ltd?
Chandra Bhagat Pharma Ltd has debt-to-equity of 0.50.
Is Chandra Bhagat Pharma Ltd a good investment?
Bull Run gives Chandra Bhagat Pharma Ltd a score of 68.3/100. This is not investment advice — consult a SEBI-registered advisor.